TALVEY™ is a prescription medicine used to treat adults with multiple myeloma who have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and their cancer has come back or did not respond to prior treatment. TALVEY™ is approved based on patient response. Data are not yet available to show if TALVEY™ improves survival or symptoms. It is not known if TALVEY™ is safe and effective in children.